National Human Genome Research Institute; Notice of Closed Meeting, 22332-22333 [2012-8943]

Download as PDF 22332 Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices Costs, Operating Costs, and/or Maintenance Costs to report. A.12–1—ESTIMATES OF ANNUAL BURDEN HOURS Number of respondents Frequency of response Average time per response (min/hour) Annual burden hours Instrument Adults ................................................ Screener (Appendix G) .................... Pre-test (Appendix A) ....................... Post-test (Appendix B) ..................... 1,875 245 245 1 1 1 2/60 20/60 40/60 63 82 163 Totals ......................................... pmangrum on DSK3VPTVN1PROD with NOTICES Type of respondents ........................................................... ........................ ........................ ........................ 308 Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Attention: NIH Desk Officer, Office of Management and Budget, at OIRA_submission@omb.eop.gov or by fax to 202–395–6974. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Patricia Weber, DrPH, Program Director, NCI/ NIH, SBIR Development Center, 6116 Executive Blvd., Suite 402, Rockville, MD 20852 or call non-toll-free number 301–594–8106 or email your request, including your address to: weberpa@mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. VerDate Mar<15>2010 14:16 Apr 12, 2012 Jkt 226001 Dated: April 9, 2012. Vivian Horovitch-Kelley, NCI Project Clearance Liaison, National Institutes of Health. 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) [FR Doc. 2012–8930 Filed 4–12–12; 8:45 am] Dated: April 6, 2012. Anna P. Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2012–8919 Filed 4–12–12; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health Center for Scientific Review; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Center for Scientific Review Advisory Council. The meeting will be open to the public with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Center for Scientific Review Advisory Council. Date: May 14, 2012. Time: 8 a.m. to 4:30 p.m. Agenda: Provide advice to the Acting Director, Center for Scientific Review (CSR), on matters related to planning, execution, conduct, support, review, evaluation, and receipt and referral of grant applications at CSR. Place: Health and Human Services Building, 5635 Fishers Lane, Rockville, MD 20852. Contact Person: Donald L Schneider, Ph.D., Senior Advisor to the Director, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3030, MSC 7776, Bethesda, MD 20892, (301) 435– 1111, schneidd@csr.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Special Emphasis Panel, H3Africa Biorepository Teleconference SEP. Date: April 18, 2012. Time: 12 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Human Genome Research Institute, 5635 Fishers Lane, 4076, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Rudy O. Pozzatti, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20852, (301) 402–0838, pozzattr@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing E:\FR\FM\13APN1.SGM 13APN1 Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: April 9, 2012. Anna P. Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–8943 Filed 4–12–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of Oncolytic Viral Cancer Therapies National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents to Jennerex Biotherapeutics (‘‘Jennerex’’) located in San Francisco, CA, USA. Intellectual Property: 1. U.S. Patent No. 7,045,313 issued May 16, 2006 entitled, ‘‘Recombinant Vaccinia Virus Containing a Chimeric Gene Having Foreign DNA Flanked by Vaccinia Regulatory DNA’’ [HHS Ref. No. E–552–1982/2–US–03]; 2. U.S. Patent No. 7,015,024 issued March 21, 2006 entitled, ‘‘Compositions Containing Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence’’ [HHS Ref. No. E–552–1982/ 2–US–04]; 3. U.S. Patent No. 7,045,136 issued May 16, 2006 entitled, ‘‘Methods of Immunization Using Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence’’ [HHS Ref. No. E– 552–1982/2–US–05]; and 4. U.S. Patent No. 6,998,252 issued February 14, 2006 entitled, ‘‘Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence’’ [HHS Ref. No. E–552–1982/ 2–US–06]. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be the U.S. and the field pmangrum on DSK3VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 14:16 Apr 12, 2012 Jkt 226001 of use may be the ‘‘development and use of Licensed Patent Rights in combination with Licensee’s proprietary or in-licensed technologies for the treatment of human cancers’’. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 14, 2012 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jennifer Wong, Senior Licensing and Patenting Manager, Cancer Branch, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4633; Facsimile: (301) 402– 0220; Email: wongje@mail.nih.gov. SUPPLEMENTARY INFORMATION: The instant technology relates to recombinant poxviruses, and in particular the vaccinia virus, as a backbone that carries a foreign DNA. The virus has been modified by inserting a chimeric gene containing foreign DNA adjacent to poxvirus transcriptional regulatory sequence. The recombinant virus is subsequently transfected into a host and the foreign gene is expressed. For example, the foreign DNA can be related to a viral pathogen, tumor-associated antigen, or therapeutic transgenes. Upon administration of the recombinant virus to a human or animal subject, the foreign gene is expressed in vivo to elicit an immune response or express the therapeutic genes. The technology takes advantage of the unique properties of poxviruses as a delivering vehicle and of the ease of preparation of such constructs. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 22333 Dated: April 10, 2012. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2012–8891 Filed 4–12–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services Agency Information Collection Activities: USCIS Case Status Online, Extension of a Currently Approved Information Collection; Comment Request 30-Day notice of information collection under review: USCIS case status online. ACTION: The Department of Homeland Security, U.S. Citizenship and Immigration Services (USCIS) is submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the Federal Register on January 30, 2012, at 77 FR 4574, allowing for a 60-day public comment period. USCIS did not receive any comments for this information collection. The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until May 14, 2012. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Department of Homeland Security (DHS), and to the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), USCIS Desk Officer. Comments may be submitted to: Chief, Regulatory Coordination Division, Office of Policy and Strategy, USCIS, DHS, 20 Massachusetts Avenue NW., Suite 5012, Washington, DC 20529–2210. Comments may also be submitted to DHS via facsimile to 202–272–8352 or via email at USCISFRComment@dhs.gov, and to the OMB USCIS Desk Officer via facsimile at 202–395–6974 or via email at oira_submission@omb.eop.gov. E:\FR\FM\13APN1.SGM 13APN1

Agencies

[Federal Register Volume 77, Number 72 (Friday, April 13, 2012)]
[Notices]
[Pages 22332-22333]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8943]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Human Genome Research Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Human Genome Research Institute 
Special Emphasis Panel, H3Africa Biorepository Teleconference SEP.
    Date: April 18, 2012.
    Time: 12 p.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Human Genome Research Institute, 5635 Fishers 
Lane, 4076, Rockville, MD 20852, (Telephone Conference Call).
    Contact Person: Rudy O. Pozzatti, Ph.D., Scientific Review 
Officer, Scientific Review Branch, National Human Genome Research 
Institute, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 
20852, (301) 402-0838, pozzattr@mail.nih.gov.

    This notice is being published less than 15 days prior to the 
meeting due to the timing

[[Page 22333]]

limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human 
Genome Research, National Institutes of Health, HHS)

    Dated: April 9, 2012.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-8943 Filed 4-12-12; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.